Paul M Beringer, PharmD

Title(s)Professor of Clinical Pharmacy
SchoolUSC School of Pharmacy
Address1985 Zonal Ave.
Health Sciences Campus
Los Angeles CA 90089-9121
Phone+1 323 442 1402
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Beringer’s research focus is on cystic fibrosis, a genetic disorder which results in defective chloride transport within the apical membrane of epithelial cells throughout the body. The principal cause of morbidity and mortality arises from chronic pulmonary infections resulting in bronchiectasis and progressive loss of lung function and eventual respiratory failure. Dr. Beringer’s group is interested in optimizing the use of pharmacologic therapies to preserve lung function and quality of life for individuals afflicted with CF.

    Ongoing research projects include: the study of the mechanistic basis of the enhanced renal clearance of antibiotics in CF; the use of novel clinical measures of glomerular filtration to improve drug dosing; and impact of pancreatic insufficiency on oral bioavailability of antibiotics.

    Biography: Dr. Beringer received his Pharm.D. degree from the USC School of Pharmacy. He completed a pharmacy practice residency and specialty residency in pharmacokinetics at the University of California at San Francisco. Currently, he is an associate professor of clinical pharmacy (USC School of Pharmacy) and associate professor of clinical medicine with the department of pulmonary and critical care medicine (USC Keck School of Medicine).

    Dr. Beringer's clinical expertise is in the area of cystic fibrosis pharmacotherapy. He has authored numerous journal articles and book chapters in the area of pharmacokinetics and cystic fibrosis.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT Pharmacometrics Syst Pharmacol. 2024 Mar 21. Hong E, Beringer PM. PMID: 38511610.
      View in: PubMed   Mentions:    Fields:    
    2. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clin Pharmacol Ther. 2024 Feb 22. Hong E, Zampoli M, Beringer PM. PMID: 38385853.
      View in: PubMed   Mentions:    Fields:    
    3. Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS). J Cyst Fibros. 2024 Jan 16. Shi A, Nguyen H, Kuo CB, Beringer PM. PMID: 38233246.
      View in: PubMed   Mentions:    Fields:    
    4. Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration. J Cyst Fibros. 2023 Nov 30. Hong E, Parsons SM, Sass L, Epstein C, Chan L, Brown C, Eshaghian PH, Beringer PM. PMID: 38036321.
      View in: PubMed   Mentions:    Fields:    
    5. Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol. 2023 Apr; 19(4):203-216. Hong E, Shi A, Beringer P. PMID: 37259485.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients. Pharmaceutics. 2023 May 08; 15(5). Hong E, Carmanov E, Shi A, Chung PS, Rao AP, Forrester K, Beringer PM. PMID: 37242680; PMCID: PMC10222456.
      View in: PubMed   Mentions: 1  
    7. Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Pharmacotherapy. 2023 04; 43(4):291-299. Hong E, Li R, Shi A, Almond LM, Wang J, Khudari AZ, Haddad S, Sislyan S, Angelich M, Chung PS, Rao AP, Beringer PM. PMID: 36866442.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2022 11 15; 66(11):e0110422. Hong E, Almond LM, Chung PS, Rao AP, Beringer PM. PMID: 36286508; PMCID: PMC9664863.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    9. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clin Pharmacol Ther. 2022 06; 111(6):1324-1333. Hong E, Almond LM, Chung PS, Rao AP, Beringer PM. PMID: 35292968; PMCID: PMC9087007.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Preclinical Pharmacokinetics and Safety of Intravenous RTD-1. Antimicrob Agents Chemother. 2022 03 15; 66(3):e0212521. Park AYJ, Tran DQ, Schaal JB, Wang M, Selsted ME, Beringer PM. PMID: 35041507; PMCID: PMC8923172.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    11. Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021 Dec 01; 23(12):2123. Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. PMID: 34519783; PMCID: PMC8643429.
      View in: PubMed   Mentions: 1     Fields:    
    12. Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction. J Org Chem. 2021 11 05; 86(21):15242-15246. Chaudhuri D, Ganesan R, Vogelaar A, Dughbaj MA, Beringer PM, Camarero JA. PMID: 34641669; PMCID: PMC8935662.
      View in: PubMed   Mentions: 2     Fields:    Translation:Cells
    13. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021 10 01; 23(10):1656-1667. Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. PMID: 33659980; PMCID: PMC8485439.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    14. Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis. Antibiotics (Basel). 2021 Aug 26; 10(9). Dughbaj MA, Jayne JG, Park AYJ, Bensman TJ, Algorri M, Ouellette AJ, Selsted ME, Beringer PM. PMID: 34572625; PMCID: PMC8466744.
      View in: PubMed   Mentions: 2  
    15. Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity. Chemistry. 2021 Sep 01; 27(49):12702-12708. Ganesan R, Dughbaj MA, Ramirez L, Beringer S, Aboye TL, Shekhtman A, Beringer PM, Camarero JA. PMID: 34159664; PMCID: PMC8410672.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    16. Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms. Sci Rep. 2019 11 15; 9(1):16905. Basso V, Tran DQ, Schaal JB, Tran P, Eriguchi Y, Ngole D, Cabebe AE, Park AY, Beringer PM, Ouellette AJ, Selsted ME. PMID: 31729441; PMCID: PMC6858451.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    17. The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. Pharmacotherapy. 2019 06; 39(6):718-723. Avedissian SN, Rhodes NJ, Ng TMH, Rao AP, Beringer PM. PMID: 31045258.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrob Agents Chemother. 2018 09; 62(9). Park AYJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM. PMID: 29914949; PMCID: PMC6125567.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    19. Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol. 2018 03; 58(3):310-319. Jayne JG, Bensman TJ, Schaal JB, Park AYJ, Kimura E, Tran D, Selsted ME, Beringer PM. PMID: 28954201; PMCID: PMC5854954.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    20. Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide. PLoS One. 2017; 12(11):e0187868. Schaal JB, Tran DQ, Subramanian A, Patel R, Laragione T, Roberts KD, Trinh K, Tongaonkar P, Tran PA, Minond D, Fields GB, Beringer P, Ouellette AJ, Gulko PS, Selsted ME. PMID: 29145473; PMCID: PMC5690597.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    21. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Antimicrob Agents Chemother. 2017 10; 61(10). Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM. PMID: 28784670; PMCID: PMC5610479.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    22. Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother. 2017 08; 61(8). Bensman TJ, Jayne JG, Sun M, Kimura E, Meinert J, Wang JC, Schaal JB, Tran D, Rao AP, Akbari O, Selsted ME, Beringer PM. PMID: 28559270; PMCID: PMC5527632.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    23. Subregional laminar cartilage MR spin-spin relaxation times (T2) in osteoarthritic knees with and without medial femorotibial cartilage loss - data from the Osteoarthritis Initiative (OAI). Osteoarthritis Cartilage. 2017 08; 25(8):1313-1323. Wirth W, Maschek S, Beringer P, Eckstein F. PMID: 28351705; PMCID: PMC5522340.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    24. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2016 Jan; 71(1):181-8. Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. PMID: 26433781; PMCID: PMC5007590.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    25. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. J Chem Inf Model. 2015 Aug 24; 55(8):1720-38. Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer PM, Neamati N. PMID: 26153616.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    26. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. Br J Pharmacol. 2014 Mar; 171(6):1551-65. Ha H, Bensman T, Ho H, Beringer PM, Neamati N. PMID: 24354854; PMCID: PMC3954492.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    27. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther. 2012 Oct; 25(5):377-82. Bensman TJ, Nguyen AN, Rao AP, Beringer PM. PMID: 22771903.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    28. Acute care clinical pharmacy practice: unit- versus service-based models. Pharmacotherapy. 2012 Feb; 32(2):e35-44. American College of Clinical Pharmacy, Haas CE, Eckel S, Arif S, Beringer PM, Blake EW, Lardieri AB, Lobo BL, Mercer JM, Moye P, Orlando PL, Wargo K. PMID: 22392430.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012 Jan; 56(1):70-4. Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ. PMID: 22024822; PMCID: PMC3256044.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    30. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011 Jul; 55(7):3278-83. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. PMID: 21576448; PMCID: PMC3122454.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    31. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011 Feb; 37(2):95-101. Wong-Beringer A, Joo J, Tse E, Beringer P. PMID: 21130609.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    32. Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus. Pharmacotherapy. 2010 Oct; 30(10):1004-10. Beringer PM, Owens H, Nguyen A, Mordwinkin N, Louie S, Mak M, Sattler F. PMID: 20874037.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    33. Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy. 2009 Feb; 29(2):236-44. Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JS, Wiederhold NP, Beringer P, Crews KR, Grabinski JL, Evens RP, Leff R, American College of Clinical Pharmacy. PMID: 19170592.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    34. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Jan; 8(1):19-25. Beringer PM, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP. PMID: 18799365.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    35. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy. 2008 Jul; 28(7):883-94. Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. PMID: 18576903.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    36. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. J Clin Pharmacol. 2008 Aug; 48(8):957-65. Liu S, Beringer PM, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B. PMID: 18511651.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    37. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J Antimicrob Chemother. 2006 May; 57(5):1017-9. Han EE, Beringer PM, Falck P, Louie S, Rao P, Shapiro B, Gill M. PMID: 16533828.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    38. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005 Dec; 49(12):5013-7. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M. PMID: 16304166; PMCID: PMC1315964.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    39. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest. 2005 Nov; 128(5):3711-6. Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL. PMID: 16304338.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    40. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005 Sep; 49(9):3676-81. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A. PMID: 16127039; PMCID: PMC1195442.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    41. Transporters and their impact on drug disposition. Ann Pharmacother. 2005 Jun; 39(6):1097-108. Beringer PM, Slaughter RL. PMID: 15886292.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    42. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. PMID: 15809878.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    43. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004 Mar; 11(3):244-52. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M. PMID: 15001403.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    44. Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clin Pharmacokinet. 2004; 43(3):145-56. Han EE, Beringer PM, Louie SG, Gill MA, Shapiro BJ. PMID: 14871154.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother. 2003 Jun; 47(6):1991-4. Sprauten PF, Beringer PM, Louie SG, Synold TW, Gill MA. PMID: 12760882; PMCID: PMC155835.
      View in: PubMed   Mentions: 6     Fields:    Translation:Cells
    46. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit. 2002 Apr; 24(2):315-21. Beringer P, Aminimanizani A, Synold T, Scott C. PMID: 11897978.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001 Dec; 45(12):3468-73. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. PMID: 11709326; PMCID: PMC90855.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    48. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001 Nov; 7(6):434-40. Beringer P. PMID: 11706322.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    49. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 2001; 40(3):169-87. Aminimanizani A, Beringer P, Jelliffe R. PMID: 11327197.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    50. Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit. 2000 Dec; 22(6):695-700. Montgomery MJ, Beringer PM, Louie SG, Gill MA. PMID: 11128237.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med. 2000 Nov; 6(6):545-50. Beringer PM, Appleman MD. PMID: 11100967.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    52. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000 Apr; 44(4):809-13. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. PMID: 10722474; PMCID: PMC89775.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    53. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med. 1999 Nov; 5(6):371-7. Beringer PM. PMID: 10570739.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. Predictive performance of a vancomycin-aminoglycoside population model. Ann Pharmacother. 1998 Feb; 32(2):176-81. Beringer PM, Wong-Beringer A, Rho JP. PMID: 9496400.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    55. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother. 1998 Jan; 41(1):142-4. Beringer PM, Vinks AA, Jelliffe RW. PMID: 9511054.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. Economic aspects of antibacterial adverse effects. Pharmacoeconomics. 1998 Jan; 13(1 Pt 1):35-49. Beringer PM, Wong-Beringer A, Rho JP. PMID: 10175984.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    57. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin. Clin Infect Dis. 1997 Oct; 25(4):936-7. Wong-Beringer A, Beringer P, Lovett MA. PMID: 9356822.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    58. Is routine measurement of free phenytoin concentrations rational? Ther Drug Monit. 1995 Aug; 17(4):381-2. Beringer PM, Rho JP. PMID: 7482694.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Paul's Networks
    Concepts (284)
    Derived automatically from this person's publications.
    Co-Authors (19)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department